Insider

Johnson & Johnson

JNJ Health Care · 5 analyses · 1 expectation tracked

Johnson & Johnson reported $25.4B in revenue (+5.9% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 1 open management expectation for this company. 1 insider sale recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Johnson & Johnson receives market authorization for OTTAVA and new oncology and hematology drugs

On October 13, 2026, Johnson & Johnson announced market authorization of the OTTAVA system – the world’s first robotic device integrated into an operating table – approval of IMAAVY for warm autoimmune hemolytic anemia (wAIHA) and the start of priority review for RYBREVANT FASPRO for advanced head and neck cancer. The moves expand the company’s portfolio in robotic surgery, hematology and oncology.

· Johnson & Johnson

Company history

October 2026

JOHNSON & JOHNSON: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-06-29 to 2026-09-27: 25,399,000,000 USD (25.4 billion; 25,399 million); same period a year earlier (2025-06-30 to 2025-09-28): 23,993,000,000 USD (24 billion; 23,993 million); change +5.9% Source
  • 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2025-12-29 to 2026-09-27: 74,771,000,000 USD (74.8 billion; 74,771 million); same period a year earlier (2024-12-30 to 2025-09-28): 69,629,000,000 USD (69.6 billion; 69,629 million); change +7.4% Source
  • 2026-10-21: Gross profit (us-gaap:GrossProfit), quarter 2026-06-29 to 2026-09-27: 17,302,000,000 USD (17.3 billion; 17,302 million); same period a year earlier (2025-06-30 to 2025-09-28): 16,690,000,000 USD (16.7 billion; 16,690 million); change +3.7% Source
  • 2026-10-21: Gross profit (us-gaap:GrossProfit), year to date 2025-12-29 to 2026-09-27: 50,517,000,000 USD (50.5 billion; 50,517 million); same period a year earlier (2024-12-30 to 2025-09-28): 47,341,000,000 USD (47.3 billion; 47,341 million); change +6.7% Source
  • 2026-10-21: Net income (us-gaap:NetIncomeLoss), quarter 2026-06-29 to 2026-09-27: 210,000,000 USD (210 million); same period a year earlier (2025-06-30 to 2025-09-28): 5,152,000,000 USD (5.2 billion; 5,152 million); change -95.9% Source
  • 2026-10-21: Net income (us-gaap:NetIncomeLoss), year to date 2025-12-29 to 2026-09-27: 10,979,000,000 USD (11 billion; 10,979 million); same period a year earlier (2024-12-30 to 2025-09-28): 21,688,000,000 USD (21.7 billion; 21,688 million); change -49.4% Source
  • 2026-10-21: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2025-12-29 to 2026-09-27: 18,850,000,000 USD (18.9 billion; 18,850 million); same period a year earlier (2024-12-30 to 2025-09-28): 17,221,000,000 USD (17.2 billion; 17,221 million); change +9.5% Source
  • 2026-10-21: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2025-12-29 to 2026-09-27: 3,732,000,000 USD (3.7 billion; 3,732 million); same period a year earlier (2024-12-30 to 2025-09-28): 2,995,000,000 USD (3 billion; 2,995 million); change +24.6% Source
  • 2026-10-21: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-27: 16,910,000,000 USD (16.9 billion; 16,910 million); previous balance (2025-12-28): 19,709,000,000 USD (19.7 billion; 19,709 million); change -14.2% Source
  • 2026-10-21: Total liabilities (us-gaap:Liabilities), as of 2026-09-27: 115,896,000,000 USD (115.9 billion; 115,896 million); previous balance (2025-12-28): 117,666,000,000 USD (117.7 billion; 117,666 million); change -1.5% Source
  • 2026-10-21: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-27: 81,529,000,000 USD (81.5 billion; 81,529 million); previous balance (2025-12-28): 81,544,000,000 USD (81.5 billion; 81,544 million); change 0% Source
  • 2026-10-21: Long-term debt (us-gaap:LongTermDebtNoncurrent), as of 2026-09-27: 35,799,000,000 USD (35.8 billion; 35,799 million); previous balance (2025-12-28): 39,438,000,000 USD (39.4 billion; 39,438 million); change -9.2% Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 27, 2026, filed October 21, 2026. SEC

LatestEarlierChange
Revenue quarter$25.4B$24B+5.9%
Net income quarter$210M$5.2B-95.9%
Diluted EPS quarter$0.09$2.12-95.8%
Operating cash flow year to date$18.9B$17.2B+9.5%
Cash and cash equivalents balance$16.9B$19.7B-14.2%
Long-term debt balance$35.8B$39.4B-9.2%

Next results expected around January 20, 2027 (estimate: the quarter ending about December 27, 2026 plus the 24 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Johnson & Johnson JNJ$25.4B+5.9%—
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • This program is expected to be substantially completed by the end of fiscal year 2026.

    Said October 13, 2026 · Period named: end of fiscal year 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
August 4, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 12, 2026Elizabeth ForminardSale notice filed13,072$284.39$3,717,546SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock209,718,001$55,520,743,704-1.1%Q3 2026
State Street133,971,339$35,467,572,287+0.1%Q3 2026
Geode Capital Management65,497,363$17,301,766,484+10.9%Q3 2026
Norges Bank (Norway's sovereign fund)31,825,084$8,082,616,583—Q2 2026
Wellington Management18,970,498$5,022,249,641-16.0%Q3 2026
Fidelity (FMR)18,663,261$4,940,911,708-17.4%Q3 2026
Capital Research Global Investors5,242,120$1,387,807,123-35.8%Q3 2026
Citadel Advisors2,743,953$726,434,117+82.8%Q3 2026
D. E. Shaw & Co.566,117$149,873,815-17.6%Q3 2026
Bridgewater Associates547,531$144,953,357-18.2%Q3 2026
Millennium Management109,905$29,096,250-81.5%Q3 2026
Soros Fund Management34,019$9,006,1900.0%Q3 2026
T. Rowe Price21,951,476$5,811,435-4.5%Q3 2026
Two Sigma Investments3,987$1,055,518-88.6%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.